Depression Research
Major depressive disorder, often referred to as major depression, is a heterogenous condition with complex and diverse neurobiological etiologies. Depression is characterized by a triad of symptoms: low or depressed mood, anhedonia and low energy or fatigue. Approximately 15% of the population in developed countries has been affected by depression in their lifetime and the chance of developing depression is twice as high in women. 40-50% of depressive causes are inheritable (genes as yet unidentified) and the remaining 50-60% of causes are caused by environmental stressors.
Depression Research Products Targets
- FGFR (5)
- Voltage-gated Calcium Channel (CaV) (38)
- Others (13)
- Glucocorticoid Receptor (9)
- Nucleoside Transporter (5)
- Glycine Transporter (6)
- GABA (10)
- Cannabinoid Transporter (10)
- Acetylcholine Transporter (1)
- D4 Receptor (12)
- 5-HT7 Receptor (11)
- 5-HT6 Receptor (14)
- 5-ht5 Receptor (2)
- 5-HT4 Receptor (17)
- NK2 Receptor (7)
- NK1 Receptor (15)
- Glutamate (Metabotropic) Group III Receptor (26)
- Glutamate (Metabotropic) Group II Receptor (33)
- Glutamate (Metabotropic) Group I Receptor (54)
- AMPA Receptor (45)
- D3 Receptor (12)
- NK3 Receptor (5)
- Vesicular Monoamine Transporter (4)
- NMDA Receptor (87)
- Kainate Receptor (22)
- D2 Receptor (14)
- D1 and D5 Receptor (16)
- Trk Receptor (13)
- Trace Amine 1 Receptor (2)
- Glutamate Transporter (18)
- Dopamine Transporter (20)
- CRF2 Receptor (3)
- CRF1 Receptor (5)
- Adrenergic Transporter (23)
- 5-HT Transporter (30)
- Vasopressin Receptor (6)
- Monoamine Oxidase (10)
- Adrenergic α2 Receptor (33)
- Adrenergic α1 Receptor (22)
- Adrenergic β3 Receptor (12)
- Adrenergic β2 Receptor (6)
- Adrenergic β1 Receptor (7)
Products for Depression Research - Page 36
- Cat.No. Product Name Information/Activity
-
BCC6631
Arcaine sulfate
14923-17-2
-
BCC6602
(R)-4-Carboxyphenylglycine
134052-68-9
-
BCC7078
CGP 37849
CGP 37849 is a potent, competitive and orally active N-methyl-D-aspartate (NMDA) receptor antagonist. CGP 37849 is an anticonvulsant in rodents and has antidepressant and anxiolytic-like effects.
-
BCC7053
CGP 39551
127910-32-1
-
BCC7087
CGP 78608 hydrochloride
CGP 78608 hydrochloride is a highly potent and selective antagonist at the glycine-binding site of the NMDA receptor, with an IC50 of 6 nM. CGP 78608 acts as a potentiator of GluN1/GluN3A-mediated glycine currents, with an estimated EC50 in the low nM range (26.3 nM). Anticonvulsant activity.
-
BCC6986
CGS 19755
110347-85-8
-
BCC7757
7-Chlorokynurenic acid sodium salt
7-Chlorokynurenic acid sodium salt (7-CKA sodium salt) is a potent and selective antagonist of the glycine B coagonist site of the N-methyl-D-aspartate (NMDA) receptor (IC50=0.56 μM). 7-Chlorokynurenic acid sodium salt is also a potent inhibitor of the reuptake of glutamate into synaptic vesicles with a Ki of 0.59 μM. 7-Chlorokynurenic acid sodium salt has potent antinociceptive actions after neuraxial delivery.
-
BCC6577
7-Chlorokynurenic acid
7-Chlorokynurenic acid (7-CKA) is a potent and selective antagonist of the glycine B coagonist site of the N-methyl-D-aspartate (NMDA) receptor (IC50=0.56 μM). 7-Chlorokynurenic acid is also a potent inhibitor of the reuptake of glutamate into synaptic vesicles with a Ki of 0.59 μM. 7-Chlorokynurenic acid has potent antinociceptive actions after neuraxial delivery.
-
BCC6805
(2R,3S)-Chlorpheg
140924-23-8
-
BCC7369
Co 101244 hydrochloride
193356-17-1


